Alluvi, formerly BI 4744, represents a promising advance in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable results in research assessments, arguably https://socialwoot.com/story24104565/alluvi-a-comprehensive-investigation-into-retatrutide-s-prospects